MedTrace Logo

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

NCT01342679 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2015-09-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate complete molecular response of Dasatinib in patients for Philadelphia chromosome-positive chronic myeloid leukemia

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

dasatinib

100mg QD

Sponsors & Collaborators

  • Epidemiological and Clinical Research Information Network

    collaborator OTHER

  • Kanto CML Study Group

    lead OTHER

Principal Investigators

  • Chikashi Yoshida, MD, PhD · National Hospital Organization, Mito Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-03-31
Completion
2014-09-30

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342679 on ClinicalTrials.gov